BioXcel Therapeutics (BTAI) PT Lowered to $25 at Guggenheim
Tweet
Share
E-mailGet Alerts BTAI Hot Sheet
Price: $1.19 --0%
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 17
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 17
Join SI Premium – FREE
Guggenheim analyst Yatin Suneja lowered the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $25.00 (from $28.00) while maintaining a Buy rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Lonking Holdings Limited (3339:HK) (LONKF) to Buy
- Freenet AG (FNTN:GR) (FRTAF) PT Lowered to EUR29 at Deutsche Bank
- Auras Technology Co Ltd (3324:TT) PT Raised to NT$1,353 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
